Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.
about
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instabilityMicrotubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied.Antibody-drug conjugates as novel anti-cancer chemotherapeuticsStructural insight into the inhibition of tubulin by vinca domain peptide ligandsStructural plasticity of tubulin assembly probed by vinca-domain ligandsStructural Basis of Microtubule Destabilization by Potent Auristatin Anti-MitoticsMarine-derived anticancer agents in clinical trials.Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.Ammosamides A and B target myosin.Potential of plant-derived natural products in the treatment of leukemia and lymphomaMechanisms of action and resistance to tubulin-binding agents.A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugsBioactive natural products from Papua New Guinea marine sponges.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Interactions of antimitotic peptides and depsipeptides with tubulin.Drugs that target dynamic microtubules: a new molecular perspectivePeptides with anticancer use or potential.The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue SarcomasEribulin for advanced breast cancer: a drug evaluation.Operationally simple and efficient workup procedure for TBAF-mediated desilylation: application to halichondrin synthesis.Evaluation of biosensor surfaces for the detection of microtubule perturbation.Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B.Potential clinical applications of halichondrins in breast cancer and other neoplasms.Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera.Eribulin -- a review of preclinical and clinical studies.Eribulin mesylate for the treatment of breast cancer.From micrograms to grams: scale-up synthesis of eribulin mesylate.Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.Biosynthesis of polyketides by trans-AT polyketide synthases.Review on the clinical use of eribulin mesylate for the treatment of breast cancer.Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine siteClinical Development of Anti-mitotic Drugs in Cancer.Photochemical oxazole-nitrile conversion downstream of rhizoxin biosynthesis and its impact on antimitotic activity.Induction of cell death by a novel naphthoquinone containing a modified anthracycline ring system.A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.A radioligand binding assay for antitubulin activity in tumor cells.
P2860
Q24610709-3CDE196B-C021-4EF2-A51E-AAA8989993C4Q24642588-FA94FBA2-CF4D-4D9A-A906-0B0EBDBDD6ECQ26800175-820CAB7F-3BC5-434F-8CBF-FBFE4E92E9C3Q27652119-6D391BB8-29AA-4407-A41E-4F35B7712426Q27681901-B5941FF0-9578-44EC-8826-58D7EF6F1025Q28553497-8DA83099-C8C6-4832-99C0-2BF9FEEAE729Q30969641-1E5FBF8E-CEF5-4BD7-9A14-CF4FFA0AB4CBQ33495209-ED38BE35-F64C-42F9-A217-95845724DCF0Q33648796-9291C53F-46AA-45A0-B00C-198821E50962Q33942845-A47CB18B-22D1-43A6-9B68-912338692A1AQ34074808-50B52F18-1337-4F64-99ED-61FE46A1B61AQ34281123-B8A4010B-45A3-4E57-BFA0-5DAE3F112454Q34451799-CB9F96DA-EEC1-4158-870A-450FABA5CF1BQ34632966-E1512044-517F-4F87-8974-0FB40751FE7FQ34972878-7B13C628-42DA-42F1-8E4C-D94DC2C50306Q35163252-84893DF6-F793-4B3B-9855-D61F184FAB06Q35167010-8BC36D82-175D-4B11-8883-D7264BA414F0Q35539229-C6641692-78C3-42D2-805C-7D49EBD05BBEQ35599745-A528F9B1-B3BA-4F7E-9124-63B5F404C66EQ36411072-EA52585C-95C6-4901-A0C9-AE151FB58E03Q36502730-F83A8E1D-A93E-483B-BAB0-B1FD93AD6572Q36674450-C5356E8D-3842-4059-AAAD-34D5B53BD859Q36763961-0906CA12-C882-4A6C-A426-C96ACBB9271FQ36845719-FA877295-E12E-477E-8C76-342E4BA256D5Q37301049-4EAD2F49-EE3A-4CB2-BFE3-E7955E4E46E0Q37351193-77DCA021-3A15-4DA4-8E4D-550B973B2474Q37356164-8DFEA73E-16D1-4681-8BD7-6D87BDFBABF4Q37360013-7FF7608D-98D5-429D-BCAD-729B93C55C13Q37637936-69D455BE-D33F-4C2C-82E3-307F37496D62Q37745070-8FD1EB44-55D8-48B5-AACE-A9FFF84B3013Q38125086-5861359E-DDCE-4F89-8F2E-E52DC3CAB0ABQ38131563-33202960-AB46-4D16-924C-ADF226234781Q38675125-853EDBAD-A908-40DC-BE8E-CC36BF06B20EQ38711371-B5050AE8-8D5C-4D73-A21E-BA7D67F65E54Q39079147-432B851A-3034-47D1-A9CA-06B0564BE71DQ39363642-E1CB5743-D2C3-4850-9815-C90A5D6FDB3BQ39373051-5305B758-D520-46FD-84B1-2E75E4E9EB15Q39491036-C01E8D04-9555-4BE0-8DD4-52BF40AA40E6Q39716005-8D9FE5DE-5261-4838-AE83-FAF73995C5C1Q40346489-B7185411-E58A-4679-9636-9F16E31FB329
P2860
Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Natural products which interac ...... 10 and 15 and halichondrin B.
@ast
Natural products which interac ...... 10 and 15 and halichondrin B.
@en
type
label
Natural products which interac ...... 10 and 15 and halichondrin B.
@ast
Natural products which interac ...... 10 and 15 and halichondrin B.
@en
prefLabel
Natural products which interac ...... 10 and 15 and halichondrin B.
@ast
Natural products which interac ...... 10 and 15 and halichondrin B.
@en
P1476
Natural products which interac ...... 10 and 15 and halichondrin B.
@en
P2093
P356
10.1016/0163-7258(92)90028-X
P577
1992-01-01T00:00:00Z